Literature DB >> 12005368

Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil.

Yukihiko Dan1, Hideyasu Murakami, Noriko Koyabu, Hisakazu Ohtani, Yasufumi Sawada.   

Abstract

Domperidone (DOM), a peripheral dopamine D2 receptor antagonist, is a substrate of P-glycoprotein (P-gp). Therefore, the transport of DOM into the brain may be restricted by P-gp function at the blood-brain barrier, and when the function of P-gp is impaired by ATP depletion under conditions of brain ischaemia (e.g. cerebral thrombosis), side-effects may be induced as a result of increased distribution of DOM into the brain. In this study, we investigated the effects of brain ischaemia and verapamil, a P-gp inhibitor, on the permeability coefficient-surface area product (PS values) of DOM across the blood-brain barrier by using an in-situ rat brain perfusion technique. The PS values of DOM were increased 3.4- and 3.6-fold after brain ischaemia for 10 and 20 min, respectively. Furthermore, co-administration of verapamil significantly increased the PS values of DOM by 42.6- and 43.3-fold in the normal and ischaemia groups, respectively. Brain vascular volume was not affected by ischaemia or verapamil. These results show that the transport of DOM into the brain is restricted by P-gp and that the brain distribution of DOM can be increased by cerebral ischaemia or co-administration of a P-gp inhibitor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12005368     DOI: 10.1211/0022357021778880

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  5 in total

1.  Oxidative stress-induced activation of Abl and Src kinases rapidly induces P-glycoprotein internalization via phosphorylation of caveolin-1 on tyrosine-14, decreasing cortisol efflux at the blood-brain barrier.

Authors:  Yutaro Hoshi; Yasuo Uchida; Masanori Tachikawa; Sumio Ohtsuki; Pierre-Olivier Couraud; Takashi Suzuki; Tetsuya Terasaki
Journal:  J Cereb Blood Flow Metab       Date:  2019-01-09       Impact factor: 6.200

2.  Itraconazole and domperidone: a placebo-controlled drug interaction study.

Authors:  Tsuneaki Yoshizato; Tsutomu Kotegawa; Hiromitsu Imai; Kimiko Tsutsumi; Junko Imanaga; Tetsuji Ohyama; Kyoichi Ohashi
Journal:  Eur J Clin Pharmacol       Date:  2012-03-15       Impact factor: 2.953

3.  Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood-Brain Barrier Permeability in Mice.

Authors:  Asuka Mizutani; Masato Kobayashi; Makoto Ohuchi; Keita Sasaki; Yuka Muranaka; Yusuke Torikai; Shota Fukakusa; Chie Suzuki; Ryuichi Nishii; Shunji Haruta; Yasuhiro Magata; Keiichi Kawai
Journal:  Pharmaceutics       Date:  2022-05-10       Impact factor: 6.525

4.  Acute Extrapyramidal Side Effects Following Domperidone Intake in a 48-Year-Old Female Patient: The First Genetic Alteration and Drug Interaction Characterized.

Authors:  Nguyen Duc Thuan; Vu Phuong Nhung; Hoang Thi Dung; Nhu Dinh Son; Nguyen Hai Ha; Nguyen Dang Ton
Journal:  J Mov Disord       Date:  2022-05-10

5.  Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro.

Authors:  Bryan A Ward; Alan Morocho; Abdullah Kandil; Raymond E Galinsky; David A Flockhart; Zeruesenay Desta
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.